c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Thoracic Oncology

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/JTO.0b013e318241655fPMID 22198430
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: A large prospective study.

  2016cited by this paper
• Utility of 10 Immunohistochemical Markers Including Novel Markers (Desmocollin-3, Glypican 3, S100A2, S100A7, and Sox-2) for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung

  2011cited by this paper
• Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status

  2010cited by this paper
• Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

  2010cited by this paper
• Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

  2010cited by this paper
• Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL).

  2010cited by this paper
• High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

  2010cited by this paper
• Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

  2009cited by this paper
• Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

  2009cited by this paper
• MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

  2009cited by this paper
• Diagnostic Pathology BioMed Central Methodology

  2009cited by this paper
• Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non–Small Cell Lung Cancer

  2008cited by this paper
• Development of automated brightfield HER2 and chromosome 17 centromere (CEN17) double in situ hybridization application for breast carcinomas and its performance comparison to manual HER2 fluorescence in situ hybridization (FISH)

  2008cited by this paper
• Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancer

  2008cited by this paper
• MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

  2008cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• Constitutive activation of c‐Met is correlated with c‐Met overexpression and dependent on cell–matrix adhesion in lung adenocarcinoma cell lines

  2007cited by this paper
• c‐Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis

  2007cited by this paper
• Pleomorphic carcinoma of the lung: a surgical outcome.

  2007cited by this paper
• Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay

  2006cited by this paper
• Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features

  2005cited by this paper
• Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

  2005cited by this paper
• The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients

  2004cited by this paper
• c-Met: Structure, functions and potential for therapeutic inhibition

  2003cited by this paper
• Scatter-factor and semaphorin receptors: cell signalling for invasive growth

  2002cited by this paper
• Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Sarcomatoid Carcinomas of the Upper Aerodigestive Tracts

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.

  1998cited by this paper
• Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis.

  1996cited by this paper
• Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance

  1996cited by this paper

• Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances

  2026cites this paper
• MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer

  2025influential citation
• Role of the HGF/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer

  2025cites this paper
• Reproducibility of c-Met Immunohistochemical Scoring (Clone SP44) for Non–Small Cell Lung Cancer Using Conventional Light Microscopy and Whole Slide Imaging

  2024cites this paper
• Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment

  2024cites this paper
• The immunohistochemical expression of c-MET and RON in lung adenocarcinoma with clinicopathologic correlation.

  2024cites this paper
• HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors

  2024cites this paper
• Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation.

  2024cites this paper
• The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC

  2024cites this paper
• MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature

  2024cites this paper
• Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy

  2024cites this paper
• MET alterations in advanced non-small cell lung cancer.

  2023cites this paper
• MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome

  2022cites this paper
• Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene

  2022cites this paper
• SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition

  2022cites this paper
• Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations

  2022cites this paper
• Amivantamab治疗EGFR/MET基因异常非小细胞肺癌的单中心经验

  2022cites this paper
• MET Amplification in Non-Small Cell Lung Cancer (NSCLC)—A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting

  2021cites this paper
• Molecular characterization and clinical impact of co-occurring mutations in patients with NSCLC harboring genomic alterations of MET.

  2021cites this paper
• Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

  2021cites this paper
• Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report

  2021influential citation
• EGFR mutation is positively correlated with C-Met protein expression: a study of 446 resected lung adenocarcinoma

  2021cites this paper
• Amivantamab: Treating EGFR Exon 20-Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation.

  2021cites this paper
• MET Exon 14 Skipping Alterations in Non-small Cell Lung Carcinoma—Current Understanding and Therapeutic Advances

  2021cites this paper
• Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models

  2021cites this paper
• Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer.

  2020cites this paper
• MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis

  2020cites this paper
• MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis

  2020cites this paper
• Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?

  2020cites this paper
• MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study

  2020cites this paper
• The analysis of surgical prognostic factors and molecular typing of locally advanced lung squamous cell carcinomas

  2020cites this paper
• Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

  2020cites this paper
• Synthesis and evaluation of 18F labeled crizotinib derivative [18F]FPC as a novel PET probe for imaging c-MET-positive NSCLC tumor.

  2020cites this paper
• MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?

  2020cites this paper
• MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis

  2020cites this paper
• Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial

  2020cites this paper
• Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation

  2020cites this paper
• Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.

  2020cites this paper
• Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14

  2020cites this paper
• MET is overexpressed in microsatellite instability-high gastric carcinoma.

  2019cites this paper
• Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies

  2019cites this paper
• AWARD NUMBER: W81XWH-17-0206 TITLE: Novel therapy strategies for mesenchymal non-small cell lung cancer PRINCIPAL INVESTIGATOR:

  2019cites this paper
• Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis

  2019cites this paper
• Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort.

  2019cites this paper
• Mesenchymal-epithelial transition gene amplification and protein overexpression in stage IV pulmonary adenocarcinoma.

  2019cites this paper
• c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.

  2019cites this paper
• The Prognostic Role of MET Protein Expression Among Surgically Resected Non-small Cell Lung Cancer Patients: A Meta-Analysis

  2019cites this paper
• The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies

  2019cites this paper
• Antibody-drug conjugates for lung cancer in the era of personalized oncology.

  2019cites this paper
• Current advances of targeting HGF/c-Met pathway in gastric cancer.

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer

  2018cites this paper
• The multiple paths towards MET receptor addiction in cancer

  2018cites this paper
• Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis

  2018influential citation
• A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib

  2018cites this paper
• Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

  2018cites this paper
• Have We Really MET a New Target?

  2018cites this paper
• Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

  2018cites this paper
• Implication du récepteur à activité tyrosine kinase (RTK) MET sur la balance survie/apoptose et identification de nouvelles mutations de RTKs dans les cancers colorectaux métastatiques

  2018cites this paper
• Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.

  2017cites this paper
• Heterogeneity of biomarker expression in non-small cell lung cancer /

  2017cites this paper
• Classification histomoléculaire des cancers pulmonaires : quoi de neuf en 2017 ?

  2017cites this paper
• Biological predictors of radiosensitivity in head and neck squamous cell carcinoma

  2017cites this paper
• MET Gene Amplification and Overexpression in Chinese Non–Small‐Cell Lung Cancer Patients Without EGFR Mutations

  2017cites this paper
• Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options

  2017cites this paper
• Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR

  2017cites this paper
• Correlation among Genetic Variations of c-MET in Chinese Patient with Non-Small Cell Lung Cancer

  2017cites this paper
• Preferential Localization of MET Expression at the Invasion Front and in Spreading Cells Through Air Spaces in Non–Small Cell Lung Carcinomas

  2017cites this paper
• The c-Met receptor: Implication for targeted therapies in colorectal cancer

  2017cites this paper
• Have Clinical Trials Properly Assessed c-Met Inhibitors?

  2017cites this paper
• MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale

  2017cites this paper
• MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma

  2017cites this paper
• Detection of MET mRNA in gastric cancer in situ. Comparison with immunohistochemistry and sandwich immunoassays

  2017cites this paper
• The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer

  2017cites this paper
• Soluble c‐Met Levels Correlated With Tissue c‐Met Protein Expression in Patients With Advanced Non–Small‐Cell Lung Cancer

  2017cites this paper
• Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer

  2017cites this paper
• MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC

  2017cites this paper
• Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

  2017cites this paper
• Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies.

  2016cites this paper
• Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin‐Fixed Paraffin Embedded Lung Adenocarcinoma Tissues

  2016cites this paper
• Has MET met its match?

  2016cites this paper
• Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non-Small-Cell Lung Cancer.

  2016cites this paper
• [Pulmonary sarcomatoid carcinoma].

  2016cites this paper
• Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.

  2016cites this paper
• Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung.

  2016cites this paper
• Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer

  2016cites this paper
• Gabriella. Synergistic activation upon MET and ALK coamplification sustains targeted therapy in sarcomatoid Carcinoma, a deadly subtype of lung

  2016cites this paper
• Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis.

  2016cites this paper
• cMET Exon 14 Skipping: From the Structure to the Clinic.

  2016influential citation
• Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays

  2016cites this paper
• MEK inhibitors against MET-amplified non-small cell lung cancer

  2016influential citation
• High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form.

  2016cites this paper
• MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis

  2016cites this paper
• Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for

  2016cites this paper
• The impact of immunohistochemistry on the classification of lung tumors

  2016cites this paper
• Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.

  2016cites this paper
• MET amplification, protein expression, and mutations in pulmonary adenocarcinoma.

  2015cites this paper
• Prognostic and predictive value of MET deregulation in non-small cell lung cancer.

  2015influential citation